-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Adicet Bio, Lowers Price Target to $100

Benzinga·03/13/2026 12:52:01
Listen to the news
Guggenheim analyst Yatin Suneja maintains Adicet Bio (NASDAQ:ACET) with a Buy and lowers the price target from $128 to $100.